Victory Capital Management
TPST icon

Victory Capital Management’s Tempest Therapeutics TPST Stock Holding History

Victory Capital Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-12
Closed -$12K – 3226
2020
Q1 		$12K Buy
+12
New +$17.5K ﹤0.01% 3026
2019
Q4 		– Sell
-7
Closed -$10K – 3231
2019
Q3 		$10K Buy
+7
New +$11.3K ﹤0.01% 3269

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.36B AUM 21.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Victory Capital Management's TPST Position: Q2 2020 in Review

Victory Capital Management sold out of Tempest Therapeutics (TPST) in Q2 2020, closing a stake of 12 shares — an estimated $12K sold.

Victory Capital Management first reported a position in TPST in Q3 2019 and held it in 2 quarters. The position peaked at $12K in Q1 2020. 51 funds tracked by Wall St. Rank hold TPST as of Q2 2020.

  • Victory Capital Management reported no remaining Tempest Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 12 Tempest Therapeutics shares in Q2 2020, an estimated $12K.
  • Victory Capital Management first reported a position in Tempest Therapeutics in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Tempest Therapeutics position peaked at $12K in Q1 2020.
  • 51 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.